Use of angiotensin converting enzyme inhibitors in patients receiving therapeutic plasma exchange with a centrifuge-based apheresis system.
adverse events
angiotensin-converting enzyme inhibitor
centrifuge-based apheresis system
plasma exchange
Journal
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
ISSN: 1744-9987
Titre abrégé: Ther Apher Dial
Pays: Australia
ID NLM: 101181252
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
revised:
23
09
2020
received:
20
06
2020
accepted:
26
09
2020
pubmed:
30
9
2020
medline:
15
12
2021
entrez:
29
9
2020
Statut:
ppublish
Résumé
Angiotensin-converting enzyme inhibitors (ACEi) are frequently used antihypertensive medications with additional advantages such as reducing proteinuria and cardiovascular events. ACEi are commonly held at least 24 hours before a therapeutic plasma exchange (TPE) to reduce possibility of adverse events (AEs) including adverse drug reactions (ADR). The objective of this study was to determine if ACEi use increases the risk of ADR in patients receiving TPE with a conventional centrifuge-based apheresis system. This is a retrospective chart review study (n = 252; 52% male). Binary logistic regression was used to analyze the association of ACEi use and AEs. Of 171 patients who had AE during TPE, only 38 patients were taking ACEi. There was no significant association between ACEi use and AEs after adjustments (odds ratio = 0.885, 95% confidence interval: 0.468, 1.674). Our results suggest that risk of AEs is not higher in patients taking ACEi receiving TPE using a centrifuge-based machine. Randomized controlled prospective trials may be needed to further investigate this matter.
Identifiants
pubmed: 32991033
doi: 10.1111/1744-9987.13589
doi:
Substances chimiques
Angiotensin-Converting Enzyme Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
497-501Informations de copyright
© 2020 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.
Références
Ward DM. Conventional apheresis therapies: A review. J Clin Apher. 2011;26(5):230-238.
Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice - Evidence-based approach from the writing Committee of the American Society for apheresis: The eighth special issue. J Clin Apher. 2019;34(3):171-354.
Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-converting enzyme inhibitors in hypertension: To use or not to use? J Am Coll Cardiol. 2018;71(13):1474-1482.
Owen HG, Brecher ME. Atypical reactions associated with use of angiotensin-converting enzyme inhibitors and apheresis. Transfusion. 1994;34(10):891-894.
Eder AF, Mitchell T, Dy B, et al. Donor survey to assess facial flushing during automated red cell collections and medication use. J Clin Apher. 2011;26(3):116-122.
Krieter DH, Steinke J, Kerkhoff M, et al. Contact activation in low-density lipoprotein apheresis systems. Artif Organs. 2005;29(1):47-52.
Perseghin P, Capra M, Baldini V, Sciorelli G. Bradykinin production during donor plasmapheresis procedures. Vox Sang. 2001;81(1):24-28.
Siami GA, Siami FS, Morrow JD, Stone WJ. Cryofiltration apheresis and plasma fractionation causing anaphylactoid reactions in patients receiving angiotensin converting enzyme inhibitors. Ther Apher. 1997;1(4):325-329.
Mortzell Henriksson M, Newman E, Witt V, et al. Adverse events in apheresis: An update of the WAA registry data. Transfus Apher Sci. 2016;54(1):2-15.
Iyer RR, Shah PH, Roy SS, Suri SK. Reducing the economic burden in management of Guillain-Barre syndrome using modified plasmapheresis. Asian J Transfus Sci. 2016;10(2):118-121.
Liew WK, Powell CA, Sloan SR, et al. Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis. JAMA Neurol. 2014;71(5):575-580.
Putensen D, Leverett D, Patel B, Rivera J. Is peripheral access for apheresis procedures underutilized in clinical practice?-a single Centre experience. J Clin Apher. 2017;32(6):553-559.
Putensen D, Pilcher L, Collier D, McInerney K. Ultrasound-guided peripheral deep vein cannulation to perform automated red cell exchange - A pilot study in a single centre. J Clin Apher. 2016;31(6):501-506.
Kojima S, Yoshitomi Y, Saotome M, Tanaka K, Shida M, Kuramochi M. Effects of losartan on low-density lipoprotein apheresis. Ther Apher. 1999;3(4):303-306.
Cyr M, Lepage Y, Blais C Jr, et al. Bradykinin and des-Arg(9)-bradykinin metabolic pathways and kinetics of activation of human plasma. Am J Physiol Heart Circ Physiol. 2001;281(1):H275-H283.
Irani MS, Toushan M, Zhang L, Simpson PM, Karafin MS. Risk of hypotensive reactions is increased when using partial saline replacement for therapeutic plasma exchange. J Clin Apher. 2019;34(5):524-527.
Szczeklik W, Wawrzycka K, Wludarczyk A, et al. Complications in patients treated with plasmapheresis in the intensive care unit. Anaesthesiol Intensive Ther. 2013;45(1):7-13.